Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib-Reference-Cited by-同舟云学术

Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib

Published:2022-06-08 Issue:5 Volume:40 Page:1105-1108
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Condoluci Adalgisa¹²^ORCID,Milan Lisa³,Forestieri Gabriela²,Terzi di Bergamo Lodovico²,Spina Valeria²,Bruscaggin Alessio²,Deambrogi Clara⁴,Moia Riccardo⁴^ORCID,Deodato Marina⁵,Fahrni Gaby⁶,Mattarucchi Roberta⁷,Merli Michele⁷^ORCID,Gerber Bernhard¹⁸,Stussi Georg¹⁹,Passamonti Francesco⁷,Gregor Michael⁶,Tedeschi Alessandra⁵^ORCID,Gaidano Gianluca⁴,Rossi Davide¹²⁹^ORCID,Ceriani Luca³⁹^ORCID

Affiliation:

1. Clinic of Hematology Oncology Institute of Southern Switzerland Ente Ospedaliero Cantonale Bellinzona Switzerland

2. Laboratory of Experimental Hematology Institute of Oncology Research Bellinzona Switzerland

3. Clinic for Nuclear Medicine and Molecular Imaging Imaging Institute of Southern Switzerland Ente Ospedaliero Cantonale Lugano Switzerland

4. Department of Translational Medicine Division of Hematology University of Eastern Piedmont Novara Italy

5. Department of Hematology ASST Grande Ospedale Metropolitano Niguarda Milan Italy

6. Division of Hematology Cantonal Hospital of Lucerne Lucerne Switzerland

7. Ospedale di Circolo of Varese & Department of Medicine and Surgery Hematology University of Insubria Varese Italy

8. University of Zurich Zurich Switzerland

9. Faculty of Biomedical Sciences Università della Svizzera italiana Lugano Switzerland

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3039

Reference10 articles.

1. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

2. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

3. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing;Frontiers in Immunology;2024-06-06